EP Patent

EP3299360A1 — Crystal forms of lenvatinib

Assigned to Indena SpA · Expires 2018-03-28 · 8y expired

What this patent protects

The present invention provides novel crystalline forms of 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, as well as methods for their preparation.

USPTO Abstract

The present invention provides novel crystalline forms of 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, as well as methods for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3299360A1
Jurisdiction
EP
Classification
—
Expires
2018-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Indena SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.